

**UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

IN RE: VALSARTAN, LOSARTAN, AND )	
IRBESARTAN PRODUCTS LIABILITY )	MDL No. 19-2875 (RBK/SAK)
LITIGATION )	
)	
This document relates to: )	<b>STATEMENT AS TO WHY NO</b>
<i>All actions</i> )	<b>BRIEF IS NECESSARY</b>
)	

Defendants Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC (collectively, “Aurobindo”) respectfully submit pursuant to L. Civ. R. 7.1(d)(4) that no brief is necessary in connection with its Motion to Substitute Settlement Counsel due to the straightforward nature of the request and because the Motion does not raise any issues of law or other issues that require explanation.

Dated: March 28, 2024

Respectfully submitted,

/s/ John P. Lavelle, Jr.  
John P. Lavelle, Jr. (NJ ID No. 004891989)  
MORGAN, LEWIS & BOCKIUS LLP  
502 Carnegie Center  
Princeton, New Jersey 08540  
Phone: 1.609.919.6688 || Fax: 1.609.919.6701  
john.lavelle@morganlewis.com

*Attorney for Defendants Aurobindo Pharma Ltd.,  
Aurobindo Pharma USA, Inc., and Aurolife Pharma  
LLC*